{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:44:38Z","timestamp":1776023078373,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,12]]},"DOI":"10.7759\/cureus.106907","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:15:57Z","timestamp":1776021357000},"source":"Crossref","is-referenced-by-count":0,"title":["Isotretinoin Use During Consolidation in Acute Promyelocytic Leukemia Following Standard All-Trans Retinoic Acid (ATRA)-Based Induction: A Case Report"],"prefix":"10.7759","author":[{"given":"Anushareddy","family":"Muddasani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel J","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Laudadio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Gentille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable","volume":"111","author":"Wang ZY","year":"2008","unstructured":"Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008, 111:2505-15. 10.1182\/blood-2007-07-102798","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco F","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al.. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013, 369:111-21. 10.1056\/NEJMoa1300874","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz MA","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, et al.. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019, 133:1630-43. 10.1182\/blood-2019-01-894980","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker U","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L, et al.. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017, 35:605-12. 10.1200\/JCO.2016.67.1982","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.7013","article-title":"Clinical availability of ATRA for patients with suspected acute promyelocytic leukemia: why guidelines may not be followed","volume":"19","author":"Geer MJ","year":"2021","unstructured":"Geer MJ, Foucar CE, Devata S, Benitez L, Perissinotti AJ, Marini BL, Bixby D. Clinical availability of ATRA for patients with suspected acute promyelocytic leukemia: why guidelines may not be followed. J Natl Compr Canc Netw. 2021, 19:1272-5. 10.6004\/jnccn.2021.7013","journal-title":"J Natl Compr Canc Netw"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"de Th\u00e9 H","year":"2010","unstructured":"de Th\u00e9 H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer. 2010, 10:775-83. 10.1038\/nrc2943","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702493","article-title":"Acne Vulgaris","volume":"379","author":"Zaenglein AL","year":"2018","unstructured":"Zaenglein AL. Acne Vulgaris. N Engl J Med. 2018, 379:1343-52. 10.1056\/NEJMcp1702493","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-961813","article-title":"All-trans-retinoic acid and 13-cis-retinoic acid: pharmacokinetics and biological activity in different cell culture models of human keratinocytes","volume":"39","author":"Schroeder M","year":"2007","unstructured":"Schroeder M, Zouboulis CC. All-trans-retinoic acid and 13-cis-retinoic acid: pharmacokinetics and biological activity in different cell culture models of human keratinocytes. Horm Metab Res. 2007, 39:136-40. 10.1055\/s-2007-961813","journal-title":"Horm Metab Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.5.2936","article-title":"Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid","volume":"77","author":"Breitman TR","year":"1980","unstructured":"Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980, 77:2936-40. 10.1073\/pnas.77.5.2936","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2020.100220","article-title":"Isotretinoin is active in the initial management of acute pro-myelocytic leukemia","volume":"14","author":"Alkhaldy HY","year":"2020","unstructured":"Alkhaldy HY, Assiri AM, Fatima S, Owaidah T. Isotretinoin is active in the initial management of acute pro-myelocytic leukemia. Leuk Res Rep. 2020, 14:2. 10.1016\/j.lrr.2020.100220","journal-title":"Leuk Res Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000541328","article-title":"A patient with acute promyelocytic leukemia treated with isotretinoin: a case report","volume":"17","author":"Goldin I","year":"2024","unstructured":"Goldin I, Medinger M, Passweg J, Halbeisen D. A patient with acute promyelocytic leukemia treated with isotretinoin: a case report. Case Rep Oncol. 2024, 17:1103-8. 10.1159\/000541328","journal-title":"Case Rep Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105163242002","article-title":"Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)","volume":"324","author":"Warrell RP Jr","year":"1991","unstructured":"Warrell RP Jr, Frankel SR, Miller WH Jr, et al.. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991, 324:1385-93. 10.1056\/NEJM199105163242002","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.6.1211.1211","article-title":"Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations","volume":"62","author":"Flynn PJ","year":"1983","unstructured":"Flynn PJ, Miller WJ, Weisdorf DJ, Arthur DC, Brunning R, Branda RF. Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. Blood. 1983, 62:1211-7. 10.1182\/blood.V62.6.1211.1211","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1984.tb02910.x","article-title":"Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia","volume":"57","author":"Nilsson B","year":"1984","unstructured":"Nilsson B. Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia. Br J Haematol. 1984, 57:365-71. 10.1111\/j.1365-2141.1984.tb02910.x","journal-title":"Br J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia","volume":"32","author":"Huang ME","year":"1989","unstructured":"Huang ME, Ye YC, Chen SR, et al.. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Haematol Blood Transfus. 1989, 32:88-96. 10.1182\/blood.V72.2.567.567","journal-title":"Haematol Blood Transfus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288112","article-title":"A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study","volume":"8","author":"Rodr\u00edguez-Veiga R","year":"2025","unstructured":"Rodr\u00edguez-Veiga R, Gil C, Sobas M, et al.. A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA\/PALG study. Haematologica. 2025, 8:2. 10.3324\/haematol.2025.288112","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.11.026","article-title":"Thrombotic events in acute promyelocytic leukemia","volume":"135","author":"Mitrovic M","year":"2015","unstructured":"Mitrovic M, Suvajdzic N, Elezovic I, et al.. Thrombotic events in acute promyelocytic leukemia. Thromb Res. 2015, 135:588-93. 10.1016\/j.thromres.2014.11.026","journal-title":"Thromb Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(20)30399-6","article-title":"Advances in the management of coagulopathy in acute promyelocytic leukemia","volume":"191","author":"Sanz MA","year":"2020","unstructured":"Sanz MA, Montesinos P. Advances in the management of coagulopathy in acute promyelocytic leukemia. Thromb Res. 2020, 191:63-7. 10.1016\/S0049-3848(20)30399-6","journal-title":"Thromb Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2107","article-title":"Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia","volume":"29","author":"Ghavamzadeh A","year":"2011","unstructured":"Ghavamzadeh A, Alimoghaddam K, Rostami S, et al.. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol. 2011, 29:2753-7. 10.1200\/JCO.2010.32.2107","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet SL","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D, et al.. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001, 19:3852-60. 10.1200\/JCO.2001.19.18.3852","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep17060066","article-title":"Acute promyelocytic leukemia: pathophysiology, diagnosis and clinical management","volume":"17","author":"Abddaoui M","year":"2025","unstructured":"Abddaoui M, Aghlallou Y, Tlem\u00e7ani I, Amrani Hassani M. Acute promyelocytic leukemia: pathophysiology, diagnosis and clinical management. Hematol Rep. 2025, 17:6. 10.3390\/hematolrep17060066","journal-title":"Hematol Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1062524","article-title":"The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions","volume":"12","author":"Iyer SG","year":"2022","unstructured":"Iyer SG, Elias L, Stanchina M, Watts J. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Front Oncol. 2022, 12:4. 10.3389\/fonc.2022.1062524","journal-title":"Front Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/474869-isotretinoin-use-during-consolidation-in-acute-promyelocytic-leukemia-following-standard-all-trans-retinoic-acid-atra-based-induction-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:15:57Z","timestamp":1776021357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/474869-isotretinoin-use-during-consolidation-in-acute-promyelocytic-leukemia-following-standard-all-trans-retinoic-acid-atra-based-induction-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.106907","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}